We are live on ! Find out more
FO

FT Options Portfolio holdings

AUM $66.4M
1-Year Est. Return 18.48%
This Fund
S&P 500
This Quarter Est. Return
+10.32%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$136M
AUM Growth
–
Cap. Flow
+$524M
Cap. Flow %
386.8%
Top 10 Hldgs %
40.45%
Holding
204
New
204
Increased
–
Reduced
–
Closed
–

Top Buys

1
GILD icon
Gilead Sciences
GILD
+$13M
2
CMG icon
Chipotle Mexican Grill
CMG
+$8.2M
3
CELG
Celgene Corp
CELG
+$6.34M
4
CMRX
Chimerix, Inc.
CMRX
+$5.55M
5
DYAX
DYAX CORPORATION
DYAX
+$5.42M

Top Sells

No sells this quarter

Sector Composition

1 Healthcare 43.09%
2 Consumer Discretionary 6.1%
3 Materials 3.81%
4 Consumer Staples 3.68%
5 Technology 2.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FMI
176
PUT
DELISTED
Foundation Medicine, Inc.
FMI
$15K 0.01%
+5,000
New +$96.4K
PFE icon
177
PUT
Pfizer
PFE
$143B
$13K 0.01%
+47,430
New +$1.49M
SYT
178
CALL
DELISTED
Syngenta Ag
SYT
$13K 0.01%
+2,500
New +$179K
VZ icon
179
CALL
Verizon
VZ
$183B
$11K 0.01%
+60,000
New +$2.72M
CLVS
180
PUT
DELISTED
Clovis Oncology, Inc.
CLVS
$11K 0.01%
+20,000
New +$1.29M
SYT
181
PUT
DELISTED
Syngenta Ag
SYT
$11K 0.01%
+10,700
New +$765K
AVGO icon
182
PUT
Broadcom
AVGO
$1.78T
$10K 0.01%
+59,000
New +$767K
HUM icon
183
CALL
Humana
HUM
$46.4B
$10K 0.01%
+1,000
New +$175K
RPTP
184
CALL
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$9K 0.01%
+198,100
New +$1.15M
AKBA icon
185
CALL
Akebia Therapeutics
AKBA
$376M
$8K 0.01%
+7,500
New +$76.5K
CCEP icon
186
PUT
Coca-Cola Europacific Partners
CCEP
$46.9B
$7K 0.01%
+10,600
New +$534K
ALDR
187
CALL
DELISTED
Alder Biopharmaceuticals
ALDR
$7K 0.01%
+5,000
New +$169K
BUD icon
188
CALL
AB InBev
BUD
$157B
$6K ﹤0.01%
+16,000
New +$1.94M
MAT icon
189
PUT
Mattel
MAT
$4.26B
$6K ﹤0.01%
+50,000
New +$1.23M
TAP icon
190
PUT
Molson Coors Class B
TAP
$7.84B
$6K ﹤0.01%
+2,500
New +$225K
BHI
191
CALL
DELISTED
Baker Hughes
BHI
$5K ﹤0.01%
+60,600
New +$3.1M
KMI icon
192
CALL
Kinder Morgan
KMI
$72.4B
$4K ﹤0.01%
+21,200
New +$505K
BCRX icon
193
CALL
BioCryst Pharmaceuticals
BCRX
$2.31B
$3K ﹤0.01%
+9,100
New +$90.5K
MDLZ icon
194
CALL
Mondelez International
MDLZ
$78.8B
$3K ﹤0.01%
+51,800
New +$2.32M
CELG
195
CALL
DELISTED
Celgene Corp
CELG
$3K ﹤0.01%
+28,800
New +$3.33M
PCRX icon
196
PUT
Pacira BioSciences
PCRX
$1.01B
$2K ﹤0.01%
+2,000
New +$113K
HOT
197
CALL
DELISTED
STARWOOD HOTELS & RESORTS WORLDWIDE, INC.
HOT
$2K ﹤0.01%
+9,000
New +$642K
DSCI
198
CALL
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$2K ﹤0.01%
+5,500
New +$26.1K
DD icon
199
CALL
DuPont de Nemours
DD
$18.1B
$1K ﹤0.01%
+1,974
New +$253K
GME icon
200
CALL
GameStop
GME
$9.84B
$1K ﹤0.01%
+59,600
New +$575K
5 6 7
8
9

Similar funds

MC
Micawber Capital Seattle, Washington $62.9M AUM 20.32% 1-Year Est. Return
FIM
Friedberg Investment Management Houston, Texas $61.9M AUM 20.07% 1-Year Est. Return
TLIC
Thai Life Insurance Company Bangkok, Thailand $71M AUM 20.14% 1-Year Est. Return
MKCM
Mount Kellett Capital Management New York $61M AUM 12.22% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
MFM
Marianas Fund Management New York $58.1M AUM 10.84% 1-Year Est. Return
VE
Vega Energy New York $75.5M AUM 15.36% 1-Year Est. Return
GFWEV
G.F.W. Energy VIII Irving, Texas $76.3M AUM 11.41% 1-Year Est. Return

FT Options's Q4 2015 Portfolio in Review

Q4 2015 is the first quarter with a 13F filing on record for FT Options, which disclosed 204 positions worth $136M. Its ten largest holdings account for 40% of the portfolio.

Its largest position is Gilead Sciences: 125,233 shares worth $12.7M.

By sector, the portfolio is most concentrated in Healthcare at 43% of assets, followed by Consumer Discretionary and Materials.

  • FT Options's largest Q4 2015 buy was Gilead Sciences: 125,233 shares worth $12.7M.
  • FT Options's ten largest holdings make up 40% of its $136M portfolio in Q4 2015.
  • FT Options disclosed 204 positions in Q4 2015, its first 13F filing on record.

Based on FT Options's 13F filing for Q4 2015, filed 5 Feb 2016.